2023 was the most memorable year on record for obesity. The American Academy of Pediatrics recognized the complex, multifactorial nature of obesity and the broad range of treatments necessary to care for pediatric patients. The first-ever triple agonist and high-potency oral GLP1 agonist was introduced with unprecedented results.
Key advances
-
The American Academy of Pediatrics published its first updated clinical practice guideline in 15 years, recognizing the complex, multifactorial nature of paediatric obesity and embracing the full range of treatment modalities, including lifestyle, pharmacotherapy, and metabolic and bariatric surgery4.
-
High-potency GLP1 agonism could only be delivered in injectable form until the oral GLP1 orforglipron study demonstrated similar efficacy to its injectable counterparts5.
-
For the first time, phase II clinical trial results demonstrated that triple-agonist, an agonist of the glucose-dependent insulinotropic polypeptide, GLP1 and glucagon receptors, retatrutide showed higher total body weight loss than any agent prior6.
This is a preview of subscription content, log in via an institution to check access.
Change history
16 February 2024
A Correction to this paper has been published: https://doi.org/10.1038/s41575-024-00908-1
References
National Academies of Sciences, Engineering, and Medicine. Current Status and Response to the Global Obesity Pandemic: Proceedings of a Workshop (National Academies Press, 2019).
Bomberg, E. M., Kyle, T. & Stanford, F. C. Considering pediatric obesity as a US public health emergency. Pediatrics 152, e2023061501 (2023).
Nutter, S. et al. Changing the global obesity narrative to recognize and reduce weight stigma: a position statement from the World Obesity Federation. Obes. Rev. https://doi.org/10.1111/obr.13642 (2023).
Hampl, S. E. et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics 151, e2022060640 (2023).
Wharton, S. et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N. Engl. J. Med. 389, 877–888 (2023).
Jastreboff, A. M. et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N. Engl. J. Med. 389, 514–526 (2023).
Kendrick, K. N. et al. Equity in obesity review. Endocrinol. Metab. Clin. North Am. 52, 617–627 (2023).
Washington, T. B. et al. Disparities in access and quality of obesity care. Gastroenterol. Clin. North Am. 52, 429–441 (2023).
Roser, P., Bajaj, S. S. & Stanford, F. C. International lack of equity in modern obesity therapy: the critical need for change in health policy. Int. J. Obes. 46, 1571–1572 (2022).
Johnson, V. R. et al. Racial disparities in obesity treatment among children and adolescents. Curr. Obes. Rep. 10, 342–350 (2021).
Acknowledgements
F.C.S. is supported by National Institutes of Health NIDDK U24 DK132733, UE5 DK137285 and P30 DK040561.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F.C.S. has served as a paid advisor/consultant to Caibrate, GoodRx, Pfizer, Eli Lilly, Boehringer Ingelheim, Gelesis, Vida Health, Life Force, Ilant Health, Melli Cell, Novo Nordisk, Clearmind Medicine, and Sweetch.
Rights and permissions
About this article
Cite this article
Stanford, F.C. A new era in obesity management. Nat Rev Gastroenterol Hepatol 21, 80–81 (2024). https://doi.org/10.1038/s41575-023-00887-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-023-00887-9
- Springer Nature Limited